Chapters

Transcript

Video

If a clinician is contemplating iDeglira or iGlarlixi in a T2D patient on an oral antidiabetic agent who is not meeting HA1c goals, should the oral medication be adjusted in any way, or discontinued?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Chantal Mathieu, MD, PhD

Chantal Mathieu, MD, PhD

Professor of Medicine
Program Director of Biomedical Sciences
Katholieke Universiteit
Chair of Endocrinology
University Hospital Gasthuisberg
Leuven, Belgium